Natasha Bilimoria, president of Friends of the Global Fight Against AIDS, Tuberculosis and Malaria, discusses the importance of faith-based organizations in battling malaria in this post on the Bill & Melinda Gates Foundation’s “Impatient Optimists” blog. “Reaching people where they live, work and worship is as important for supporters as…
The Global Fund to Fight AIDS, Tuberculosis and Malaria, which “froze disbursements of its AIDS grant to China in November and all other grants in May over suspected misuse of the money and the government’s reluctance to involve community groups, … said Tuesday that it was lifting the freeze on financing to ensure that AIDS work in China continued while it worked with government officials, representatives from United Nations agencies and private groups to resolve the dispute,” the Associated Press reports.
In a Malaria Policy Center “Malaria Watch TV” video post, U.S. Global Malaria Coordinator Rear Admiral Tim Ziemer “speak[s] with the Malaria Policy Center about the status of the malaria fight and how the U.S. is leading the way against this preventable and treatable disease,” the organization writes. The “U.S.…
With the new knowledge that providing antiretroviral (ARV) treatment to people living with HIV “contribut[es] to a sharp slowdown in the spread of the virus,” “scaling up treatment now may prove to be the least expensive option if we want to bring this deadly pandemic, which still infects 1.8 million people every year, under control,” Michel Kazatchkine, executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria writes in the Guardian’s “Poverty Matters Blog.”
Several donors to the Global Fund to Fight AIDS, Tuberculosis and Malaria “continue to hold back their contributions for this year â€¦ add[ing] up to more than $500 million that the Global Fund had been counting on for this year out of a total budget of about $3 billion,” the Lancet reports.
“Reducing commodity costs [for antiretroviral drugs] by a mere five to 10 percent can represent hundreds of millions of dollars in savings for the global community. In turn these savings translate into millions of more patients who can receive access to life-saving treatment,” David de Ferranti, president of Results for Development Institute (R4D), and Kanika Bahl, managing director at R4D, write in a Huffington Post opinion piece. They discuss a strategic plan for increasing access to and lowering the cost of antiretroviral drugs (ARVs) that R4D developed for the Global Fund to Fight AIDS, Tuberculosis and Malaria.
“The neglected tropical diseases (NTDs) produce a devastating level of chronic disability in sub-Saharan Africa, with some estimates suggesting that the NTD disease burden exceeds tuberculosis and is one-half that of malaria,” Julie Noblick and Richard Skolnick of George Washington University and Peter Hotez of the Sabin Vaccine Institute write in a PLoS Neglected Tropical Diseases editorial. With noted relationships between the prevalence of NTDs and HIV, the diseases “demand a public health response from the established global HIV/AIDS community, in parallel with efforts to scale up NTD control,” they argue.
“Scientists have now provided revolutionary tools to roll back HIV but only a major funding boost, supported especially by emerging giant economies, will determine the outcome,” according to experts speaking in Rome at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Agence France-Presse reports.
Following an audit last year by the Global Fund to Fight AIDS, Tuberculosis and Malaria that found Papua New Guinea’s National Department of Health (NDOH) “had not complied with grant guidelines and some $7 million had been misdirected,” the government is stepping down as the principal recipient (PR) of Global Fund grants in order to “improve its response,” IRIN reports.
Cutting AIDS funding to China will “be a big mistake for a donor and particularly, for anyone who’s invested in China today, … for the simple reason that this funding is a catalytic fund,” UNAIDS Executive Director Michel Sidibe told Reuters in an interview on Monday.